78750-68-2

Usage

Uses

Used in Pharmaceutical Industry:
4-[(3-aminopyridin-2-yl)amino]phenol is used as a research compound for studying the role of BRD4 in various diseases, such as cancer and inflammatory disorders. Its potent and selective inhibition of BRD4 makes it a valuable tool in understanding the underlying mechanisms of these conditions and identifying potential therapeutic targets.
Used in Drug Development:
4-[(3-aminopyridin-2-yl)amino]phenol is used as a starting point for the development of new treatments for diseases involving BRD4 dysregulation. Its potential as a therapeutic agent has been demonstrated in preclinical studies, and ongoing research aims to further explore its efficacy and safety in treating various conditions.
Used in Academic Research:
4-[(3-aminopyridin-2-yl)amino]phenol is used as a research tool in academic institutions to investigate the molecular mechanisms of BRD4 and its role in gene regulation and cell growth. This knowledge can contribute to a better understanding of the pathophysiology of diseases associated with BRD4 and aid in the discovery of novel therapeutic strategies.

Upstream product

• 78750-61-5 4-[(3-nitropyridin-2-yl)amino]phenol 
• 123-30-8 4-amino-phenol 
• 5470-18-8 2-Chloro-3-nitropyridine 

Downstream Products

• 141430-65-1 N-[2-(4-hydroxy-phenylamino)-pyridin-3-yl]-4-methoxy-benzenesulfonamide 
• 141450-48-8 N-[2-(4-hydroxy-phenylamino)-pyridin-3-yl]-4-methoxy-benzenesulfonamide hydrochloride 
• 141449-98-1 4-Methoxy-N-[2-[[4-(4-methoxybenzenesulfonyloxy)phenyl]amino]-3-pyridyl]benzenesulfonamide 

Relevant academic research and scientific papers

Synthesis and biological evaluation of 1-benzyl-N-(2-(phenylamino)pyridin-3-yl)-1H-1,2,3-triazole-4-carboxamides as antimitotic agents

A library of 1-benzyl-N-(2-(phenylamino)pyridin-3-yl)-1H-1,2,3-triazole-4-carboxamides (7a–al) have been designed, synthesized and screened for their anti-proliferative activity against some selected human cancer cell lines namely DU-145, A-549, MCF-7 and HeLa. Most of them have shown promising cytotoxicity against lung cancer cell line (A549), amongst them 7f was found to be the most potent anti-proliferative congener. Furthermore, 7f exhibited comparable tubulin polymerization inhibition (IC50 value 2.04 μM) to the standard E7010 (IC50 value 2.15 μM). Moreover, flow cytometric analysis revealed that this compound induced apoptosis via cell cycle arrest at G2/M phase in A549 cells. Induction of apoptosis was further observed by examining the mitochondrial membrane potential and was also confirmed by Hoechst staining as well as Annexin V-FITC assays. Furthermore, molecular docking studies indicated that compound 7f binds to the colchicine binding site of the β-tubulin. Thus, 7f exhibits anti-proliferative properties by inhibiting the tubulin polymerization through the binding at the colchicine active site and by induction of apoptosis.

Synthesis and crystal structures of 4-(3-nitropyridin-2-ylamino)phenol and 4-(3-aminopyridin-2-ylamino)phenol

The title compounds, 4-(3-nitropyridin-2-ylamino)phenol (I) and 4-(3-aminopyridin-2-ylamino)phenol (II), are two intermediates for the synthesis of a potential antitumor agent ABT-751. The reaction of 4-aminophenol with 2-chloro-3-nitropyridine yielded I

Crystalline N-(2-((4-hydroxyphenyl)amino)pyridin-3-yl)-4-methoxybenzenesulfonamide hydrochloride

Crystalline N-(2-((4-hydroxyphenyl)amino)pyridin-3-yl)-4-methoxybenzenesulfonamide hydrochloride, ways to make it, compositions containing it and methods of treatment of diseases using it are disclosed.

N-(2-((4-HYDROXYPHENYL)AMINO)PYRIDIN-3-YL)-4-METHOXYBENZENESULFONAMIDE CRYSTALLINE FORM 1

N-(2-((4-Hydroxyphenyl)amino)pyridin-3-yl)-4-methoxybenzenesulfonamide Crystalline Form 1, ways to make it, compositions containing it and methods of treatment of diseases using it are disclosed.

N-((2Z)-2-((4-HYDROXYPHENYL)IMINO)-1,2-DIHYDRO-3-PYRIDINYL)-4-METHOXYBENZENESULFONAMIDE CRYSTALLINE FORM 2

N-((2Z)-2-((4-Hydroxyphenyl)imino)-1,2-dihydro-3-pyridinyl)-4-methoxybenzenesulfonamide Crystalline Form 2, ways to make it, compositions containing it and methods of treatment of diseases using it are disclosed.

Amorphous N-(2-((4-hydroxyphenyl)amino)pyridin-3-yl)-4-methoxybenzenesulfonamide

An amorphous drug, processes for making it, compositions containing it and methods of treatment of diseases using it are disclosed.

Amorphous N-(2-((4-hydroxyphenyl)amino)pyridin-3-yl)-4-methoxybenzenesulfonamide hydrochloride

Amorphous N-(2-((4-hydroxyphenyl)amino)pyridin-3-yl)-4-methoxybenzenesulfonamide hydrochloride, processes for making it, compositions containing it and methods of treatment of diseases using it are disclosed.

Sulfonamide derivatives

Sulfonamide derivatives of the general formula (I): STR1 wherein preferably R1 represents a lower alkoxy group, R2, R3, R4, R5, R6 and R7 are as defined in the specification, A and B may be the same or different from each other and each represents =N-- or =CH--, E represents an aromatic 6-membered cyclic group, which may have 1 or 2 nitrogen atoms in the ring, and may be substituted with 1 to 3 substituents which may be the same or different from one another with the proviso that a combination of R1 which is a hydrogen atom, lower alkyl group, nitro group or amino group which may be protected, R2 and R3 which are each a hydrogen atom, A and B which are each =CH-- and E which is a phenyl group which may be substituted with 1 to 3 substituents G which may be the same or different from one another is excluded, or pharmacologically acceptance salts of them.